(Q44375851)

2 December 2017

title

PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? (English)

1 reference

2 December 2017

1 reference

Pietro Pepe

1

1 reference

2 December 2017

Filippo Fraggetta

2

1 reference

2 December 2017

Antonio Galia

3

1 reference

2 December 2017

Giorgio Skonieczny

4

1 reference

2 December 2017

Francesco Aragona

5

1 reference

2 December 2017

publication date

1 July 2012

1 reference

International Brazilian Journal of Urology

2 December 2017

published in

1 reference

2 December 2017

volume

38

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

489-495

1 reference

Screening and prostate-cancer mortality in a randomized European study

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Urinary PCA3 score predicts prostate cancer multifocality

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Urinary prostate cancer 3 test: toward the age of reason?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Contemporary role of prostate cancer gene 3 in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382012000400008

10.1590/S1677-55382012000400008

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference